Evaluating Antibiotic Stewardship Assisted by Computer in the University

Status Not yet recruiting

Clinical Trial Summary

Antibiotic resistance is one of the most pressing health threats that mankind faces now and in the coming decades. Antibiotic resistance leads to longer hospital stays, higher medical costs and increased mortality. In order to tackle antibiotic resistance, a computerized-decision support system (CDSS) facilitating antibiotic stewardship and an electronic surveillance software (ESS) facilitating infection prevention and control activities will implement in our tertiary care university hospital. The investigators conduct a pragmatic, prospective, single-centre, before-after uncontrolled study with an interrupted time-series analysis 12 months before and 12 months after the introduction of the CDSS for antibiotic stewardship (APSS) and ESS for infection surveillance (ZINC). APSS and ZINC will assist respectively the antibiotic stewardship and the infection prevention and control teams of Nancy University Hospital (France). The investigators will evaluate the impact of the CDSS/ESS on the antibiotic use in adult (≥ 18 years) inpatients (hospitalised ≥ 48h). The primary outcome is the prescription rate by all healthcare professionals from the hospital of all systemic antibiotics expressed in defined daily doses/1 000 patients/month. Concurrently, the investigators will assess the safety of the intervention, its impact on the appropriateness of antibiotic prescriptions and on additional precautions (isolation precautions) as recommended in guidelines, and on bacterial epidemiology (multidrug-resistant bacteria and Clostridioides difficile infections) in the hospital. Finally, the investigators will evaluate the users' satisfaction and the cost of this intervention from the hospital perspective.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04976829
Study type	Observational
Source	Central Hospital, Nancy, France
Contact	Arnaud Florentin, Dr
Phone	+33383155293
Email	a.florentin@chu-nancy.fr
Status	Not yet recruiting
Phase
Start date	September 1, 2021
Completion date	September 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05589727` - Application of Ventilator-Associated Events (VAE) in Ventilator-Associated Pneumonia (VAP) Notified in Brazil
Completed	`NCT04873557` - Copper Use as Protection Against Antimicrobial Resistance in the ICU	N/A
Completed	`NCT03843021` - Ventricular Assist Device (VAD) Infection Prevention Survey
Recruiting	`NCT04579094` - Prevalence and Risk Factors for the Carriage of Bacteria and Clostridioid in Elderly Dependent Persons
Recruiting	`NCT04192435` - Tranexamic Acid to Reduce Infection After Gastrointestinal Surgery	Phase 4
Recruiting	`NCT06216080` - Dynamic Full-Field Optical Coherence Tomography for Structural and Microbiological Characterization of Central Venous Catheter-deposited Biofilm in Critically Ill Patients
Enrolling by invitation	`NCT03924934` - Community-associated Highly-Resistant Enterobacterales
Recruiting	`NCT06379139` - Dynamic Full-field Optical Coherence Tomography for Structural and Microbiological Characterization of Endotracheal Tube Biofilm in Critically Ill Patients
Recruiting	`NCT06155747` - Transmission and Acquisition of Nontuberculous Mycobacteria Outbreak Investigation (TrANsMIt)
Completed	`NCT03349268` - Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection	N/A
Completed	`NCT04053257` - Effect of Video Camera Monitoring Feedback on Hand Hygiene Compliance and Infections in NICU	N/A
Not yet recruiting	`NCT03189043` - Controlled Crossover Study of AIONX Antimicrobial Surface for the Prevention of Healthcare-associated Infections	Phase 2
Completed	`NCT05797818` - Red Light Photobiomodulation and Topical Disinfectants	Phase 1/Phase 2
Terminated	`NCT03361085` - Modular Prevention Bundle for Non-ventilator-associated Hospital-acquired Pneumonia (nvHAP)	N/A
Completed	`NCT04770597` - Monitors to Improve Indoor Carbon Dioxide (CO2) Concentrations in the Hospital	N/A
Recruiting	`NCT05612672` - Evaluation of GeoHAI Implementation	N/A
Completed	`NCT02605499` - Ultra Violet-C Light Evaluation as an Adjunct to Removing Multi-Drug Resistant Organisms (UVCLEAR-MDRO)	N/A
Completed	`NCT04676581` - Risk Benefit Ratio of Hirudotherapy: Retrospective Single-center Study of 37 Cases Over a Period of 9 Years
Recruiting	`NCT05979545` - EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics	Phase 4
Active, not recruiting	`NCT04312243` - NO Prevention of COVID-19 for Healthcare Providers	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluating Antibiotic Stewardship Assisted by Computer in the University Hospital of Nancy (MACABAO) — MACABAO

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms